Viking Therapeutics: Soaring Stock, But Is it Worth the Ride? Viking Therapeutics has been a hot stock in 2024, with its share price skyrocketing over 240% since the start of the year.

Viking Therapeutics shares fall in Wednesday's after-hours session after the company reported financial results for the ...

Analysts expect Viking Therapeutics to report an earnings per share (EPS) of $-0.44. The announcement from Viking ...

Viking Therapeutics, Inc. ( NASDAQ: VKTX) Q2 2025 Earnings Conference Call July 23, 2025 4:30 PM ET Brian Lian - President, CEO & Director Gregory Zante - Chief Financial Officer ...

Viking Therapeutics reported a solid financial standing with $808 million in cash, cash equivalents, and short-term investments. This strong cash position provides a substantial financial runway to ...

Viking Therapeutics has strong R&D, dual-track obesity drugs, and solid cash runway. Click here to read an analysis of VKTX ...

Every investor in Viking Therapeutics, Inc. (NASDAQ:VKTX) should be aware of the most powerful shareholder groups. We can see that institutions own the lion's share in the company with 70% ownership.

In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Viking Therapeutics, with a price target of $70.00. The company’s shares closed yesterday at $33.50. Take ...

Viking Therapeutics ( ($VKTX) ) has risen by 7.76%. Read on to learn why. Viking Therapeutics has seen a notable 7.76% ...

Viking Therapeutics (NASDAQ: VKTX) just gave shareholders a few more reasons to be excited for the future. With its shares soaring by a stunning 34% on July 25 thanks to second-quarter earnings ...

We came across a bullish thesis on Viking Therapeutics, Inc. on r/wallstreetbets subreddit by Dritzz-9966. In this article, ...

Viking Therapeutics posted results of an experimental drug that showed even better weight loss than the current market-leading drugs, a sign that the dominance of Ozempic and Mounjaro is far from ...